Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice

Psychopharmacology

Volumn 192, Issue 1, 2007, Pages 97-110

  Thomsen, Morgane ^a   Wörtwein, Gitta ^b,c   Fink Jensen, Anders ^b,c   Woldbye, David P D ^b,c   Wess, Jürgen ^d   Caine, S Barak ^a  

^a MCLEAN HOSPITAL   (United States)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acetylcholine receptor; Antipsychotic; Knockout mice; M5; Muscarinic; Prepulse inhibition; Psychostimulant

Indexed keywords

CLOZAPINE; COCAINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PSYCHOSTIMULANT AGENT; TRIHEXYPHENIDYL;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; GENOTYPE; HETEROZYGOTE; HYPOTHESIS; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; COCAINE; DEXTROAMPHETAMINE; DOPAMINE AGONISTS; FEMALE; GENOTYPE; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCARINIC AGONISTS; RECEPTORS, MUSCARINIC; REFLEX; SCHIZOPHRENIA; STARTLE REACTION; TRIHEXYPHENIDYL;

EID: 34247629419     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0682-y     Document Type: Article

References (89)

1. Allen TB, McEvoy JP (2002) Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159:1244-1245
2. Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, Werge T (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 28:1168-1175
3. Bartus RT (1979) Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 206:1087-1089
4. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M, Wess J (2002) Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 99:11452-11457
5. Bernard V, Normand E, Bloch B (1992) Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 12:3591-3600
6. Blaha CD, Allen LF, Das S, Inglis WL, Latimer MP, Vincent SR, Winn P (1996) Modulation of dopamine efflux in the nucleus accumbens after cholinergic stimulation of the ventral tegmental area in intact, pedunculopontine tegmental nucleus-lesioned, and laterodorsal tegmental nucleus-lesioned rats. J Neurosci 16:714-722
7. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473
8. Bolam JP, Francis CM, Henderson Z (1991) Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunocytochemical study. Neuroscience 41:483-494
9. Bora E, Veznedaroglu B, Kayahan B (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28:139-141
10. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258
11. Buchanan RW, Summerfelt A, Tek C, Gold J (2003) An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29-33
12. Bymaster FP, Falcone JF (2000) Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur J Pharmacol 390:245-248
13. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003) Muscarinic mechanisms of antipsychotic atypicality. Prog Neuro-psychopharmacol Biol Psychiatry 27:1125-1143
14. Chapman CA, Yeomans JS, Blaha CD, Blackburn JR (1997) Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience 76:177-186
15. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88(1-3):63-72
16. Chintoh A, Fulton J, Koziel N, Aziz M, Sud M, Yeomans JS (2003) Role of cholinergic receptors in locomotion induced by scopolamine and oxotremorine-M. Pharmacol Biochem Behav 76:53-61
17. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
18. Crook JM, Dean B, Pavey G, Copolov D (1999) The binding of [3H] AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64:1761-1771
19. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL (2005) The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) 178:451-460
20. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS (1978) Physostigmine: improvement of long-term memory processes in normal humans. Science 201:272-274
21. De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL (2004) Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 50:124-127
22. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083-1091
23. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP (1993) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820
24. Dulawa SC, Hen R, Scearce-Levie K, Geyer MA (1997) Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl) 132:125-134
25. Egashira N, Tanoue A, Higashihara F, Fuchigami H, Sano K, Mishima K, Fukue Y, Nagai H, Takano Y, Tsujimoto G, Stemmelin J, Griebel G, Iwasaki K, Ikeda T, Nishimura R, Fujiwara M (2005) Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs. Neuropsychopharmacology 30:1996-2005
26. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA (2005) Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 28:179-184
27. Ferreri F, Agbokou C, Gauthier S (2006) Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31:369-376
28. Forster GL, Blaha CD (2000) Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 12:3596-3604
29. Forster GL, Blaha CD (2003) Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur J Neurosci 17:751-762
30. Forster GL, Yeomans JS, Takeuchi J, Blaha CD (2002) M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci 22: RC190
31. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC (2005) Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181:358-363
32. Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174:45-53
33. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349-357
34. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
35. Goldschmidt PL, Savary L, Simon P (1984) Comparison of the stimulatory effects of eight antiparkinsonian drugs. Prog Neuro-psychopharmacol Biol Psychiatry 8:257-261
36. Goudie AJ, Smith JA, Taylor A, Taylor MA, Tricklebank MD (1998) Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699-710
37. Halpern JH (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131-138
38. Heldt SA, Green A, Ressler KJ (2004) Prepulse inhibition deficits in GAD65 knockout mice and the effect of antipsychotic treatment. Neuropsychopharmacology 29:1610-1619
39. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI (1994) Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14:3351-3363
40. Hohnadel E, Bouchard K, Terry AV Jr (2006) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology (in press)
41. Ince E, Ciliax BJ, Levey AI (1997) Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27:357-366
42. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, Gamble SJ (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 13:513-527
43. Jones CK, Shannon HE (2000a) Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur J Pharmacol 391:105-112
44. Jones CK, Shannon HE (2000b) Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 294:1017-1023
45. Kelley BM, Porter JH (1997) The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav 57:707-719
46. Kinkead B, Dobner PR, Egnatashvili V, Murray T, Deitemeyer N, Nemeroff CB (2005) Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J Pharmacol Exp Ther 315:256-264
47. Kumari V, Zachariah E, Galea A, Mehrotra R, Taylor D, Sharma T (2001) Effects of procyclidine on prepulse inhibition of the acoustic startle response in healthy human volunteers. Psychopharmacology (Berl) 154:221-229
48. Kumari V, Aasen I, Ffytche D, Williams SC, Sharma T (2006) Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. NeuroImage 29:545-556
49. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627
50. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-3226
51. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ (1995) Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 15:4077-4092
52. McCaughran J Jr, Mahjubi E, Decena E, Hitzemann R (1997) Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl) 134:131-139
53. Mendelsohn E, Rosenthal M, Bohiri Y, Werber E, Kotler M, Strous RD (2004) Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 19:319-324
54. Michal P, Lysikova M, El-Fakahany EE, Tucek S (1999) Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 376:119-125
55. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2004) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79-104
56. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. The National Academies Press, Washington, D.C.
57. Newell KA, Zavitsanou K, Jew SK, Huang XF (2007) Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (in press)
58. Nielsen EB (1988) Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology (Berl) 94:115-118
59. Oakman SA, Faris PL, Kerr PE, Cozzari C, Hartman BK (1995) Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J Neurosci 15:5859-5869
60. Olianas MC, Maullu C, Onali P (1997) Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122:401-408
61. Olianas MC, Maullu C, Onali P (1999) Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20:263-270
62. Onali P, Olianas MC (2002) Muscarinic M4 receptor inhibition of dopamine D1-like receptor signalling in rat nucleus accumbens. Eur J Pharmacol 448:105-111
63. Perry EK, Perry RH (1995) Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28:240-258
64. Prus AJ, Baker LE, Meltzer HY (2004) Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77:199-208
65. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR (2000) In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23:56-68
66. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR (2003a) Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28:1531-1537
67. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR (2003b) In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatr 160:118-127
68. Ralph RJ, Caine SB (2005) Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther 312:733-741
69. Ralph RJ, Paulus MP, Geyer MA (2001) Strain-specific effects of amphetamine on prepulse inhibition and patterns of locomotor behavior in mice. J Pharmacol Exp Ther 298:148-55
70. Reever CM, Ferrari-DiLeo G, Flynn DD (1997) The M5 (m5) receptor subtype: fact or fiction? Life Sci 60:1105-1112
71. Rosse RB, Deutsch SI (2002) Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25:272-275
72. Russig H, Spooren W, Durkin S, Feldon J, Yee BK (2004) Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment. Psychopharmacology (Berl) 175:143-147
73. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259
74. Sipos ML, Burchnell V, Galbicka G (1999) Dose-response curves and time-course effects of selected anticholinergics on locomotor activity in rats. Psychopharmacology (Berl) 147:250-256
75. Sipos ML, Burchnell V, Galbicka G (2001) Effects of selected anticholinergics on acoustic startle response in rats. J Appl Toxicol 21(Suppl 1):S95-S101
76. Sitaram N, Weingartner H, Gillin JC (1978) Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science 201:274-276
77. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782-792
78. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N- desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679
79. Takeuchi J, Fulton J, Jia ZP, Abramov-Newerly W, Jamot L, Sud M, Coward D, Ralph M, Roder J, Yeomans J (2002) Increased drinking in mutant mice with truncated M5 muscarinic receptor genes. Pharmacol Biochem Behav 72:117-123
80. Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A (2004) A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 7:117-123
81. Vilaro MT, Palacios JM, Mengod G (1990) Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 114:154-159
82. Wang H, Ng K, Hayes D, Gao X, Forster G, Blaha C, Yeomans J (2004) Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the m5 muscarinic receptor gene found in the human 15q schizophrenia region. Neuropsychopharmacology 29:2126-2139
83. Weiner DM, Levey AI, Brann MR (1990) Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87:7050-7054
84. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177:207-216
85. 5 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 98:14096-14101
86. Yeomans J, Forster G, Blaha C (2001) M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci 68:2449-2456
87. Zavitsanou K, Katsifis A, Mattner F, Huang X-F (2004) Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29:619-625
88. Zhang W, Yamada M, Gomeza J, Basile AS, Wess J (2002) Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J Neurosci 22:6347-6352
89. Zorn SH, Jones SB, Ward KM, Liston DR (1994) Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269:R1-R2